Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT510 vs Bevacizumab in First-line Non-squamous NSCLC
NCT03792074Phase 3Unknown
- Sponsor
- Sinocelltech Group Limited
- Start
- Feb 2019
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of SCT510A in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Sinocelltech Group Limited. Primary endpoint: Objective Response Rate at 12 weeks. Status: unknown.
02
Drugs
SCT510A
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03792074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792074.